Updating the OMERACT filter : core areas as a basis for defining core outcome sets
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Filter provides guidelines for the development and validation of outcome measures for use in clinical research. The "Truth" section of the OMERACT Filter presupposes an explicit framework for identifying the relevant core outcomes that are universal to all studies of the effects of intervention effects. There is no published outline for instrument choice or development that is aimed at measuring outcome, was derived from broad consensus over its underlying philosophy, or includes a structured and documented critique. Therefore, a new proposal for defining core areas of measurement ("Filter 2.0 Core Areas of Measurement") was presented at OMERACT 11 to explore areas of consensus and to consider whether already endorsed core outcome sets fit into this newly proposed framework.
METHODS: Discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed framework, whether these observations had a more general application, and what issues remained to be resolved.
RESULTS: Although there was broad acceptance of the framework in general, several important areas of construction, presentation, and clarity of the framework were questioned. The discussion groups and subsequent feedback highlighted 20 such issues.
CONCLUSION: These issues will require resolution to reach consensus on accepting the proposed Filter 2.0 framework of Core Areas as the basis for the selection of Core Outcome Domains and hence appropriate Core Outcome Sets for clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
The Journal of rheumatology - 41(2014), 5 vom: 12. Mai, Seite 994-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kirwan, John R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CLINICAL TRIALS |
|---|
| Anmerkungen: |
Date Completed 04.02.2015 Date Revised 10.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3899/jrheum.131309 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM236444026 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM236444026 | ||
| 003 | DE-627 | ||
| 005 | 20231224105600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3899/jrheum.131309 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0788.xml |
| 035 | |a (DE-627)NLM236444026 | ||
| 035 | |a (NLM)24634204 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kirwan, John R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Updating the OMERACT filter |b core areas as a basis for defining core outcome sets |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.02.2015 | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Filter provides guidelines for the development and validation of outcome measures for use in clinical research. The "Truth" section of the OMERACT Filter presupposes an explicit framework for identifying the relevant core outcomes that are universal to all studies of the effects of intervention effects. There is no published outline for instrument choice or development that is aimed at measuring outcome, was derived from broad consensus over its underlying philosophy, or includes a structured and documented critique. Therefore, a new proposal for defining core areas of measurement ("Filter 2.0 Core Areas of Measurement") was presented at OMERACT 11 to explore areas of consensus and to consider whether already endorsed core outcome sets fit into this newly proposed framework | ||
| 520 | |a METHODS: Discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed framework, whether these observations had a more general application, and what issues remained to be resolved | ||
| 520 | |a RESULTS: Although there was broad acceptance of the framework in general, several important areas of construction, presentation, and clarity of the framework were questioned. The discussion groups and subsequent feedback highlighted 20 such issues | ||
| 520 | |a CONCLUSION: These issues will require resolution to reach consensus on accepting the proposed Filter 2.0 framework of Core Areas as the basis for the selection of Core Outcome Domains and hence appropriate Core Outcome Sets for clinical trials | ||
| 650 | 4 | |a Consensus Development Conference | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CLINICAL TRIALS | |
| 650 | 4 | |a CONSENSUS DEVELOPMENT CONFERENCE | |
| 650 | 4 | |a OUTCOME AND PROCESS ASSESSMENT | |
| 650 | 4 | |a OUTCOME MEASURES IN RHEUMATOLOGY | |
| 700 | 1 | |a Boers, Maarten |e verfasserin |4 aut | |
| 700 | 1 | |a Hewlett, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Beaton, Dorcas |e verfasserin |4 aut | |
| 700 | 1 | |a Bingham, Clifton O |c 3rd |e verfasserin |4 aut | |
| 700 | 1 | |a Choy, Ernest |e verfasserin |4 aut | |
| 700 | 1 | |a Conaghan, Philip G |e verfasserin |4 aut | |
| 700 | 1 | |a D'Agostino, Maria-Antonietta |e verfasserin |4 aut | |
| 700 | 1 | |a Dougados, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Furst, Daniel E |e verfasserin |4 aut | |
| 700 | 1 | |a Guillemin, Francis |e verfasserin |4 aut | |
| 700 | 1 | |a Gossec, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a van der Heijde, Désirée M |e verfasserin |4 aut | |
| 700 | 1 | |a Kloppenburg, Margreet |e verfasserin |4 aut | |
| 700 | 1 | |a Kvien, Tore K |e verfasserin |4 aut | |
| 700 | 1 | |a Landewé, Robert B M |e verfasserin |4 aut | |
| 700 | 1 | |a Mackie, Sarah L |e verfasserin |4 aut | |
| 700 | 1 | |a Matteson, Eric L |e verfasserin |4 aut | |
| 700 | 1 | |a Mease, Philip J |e verfasserin |4 aut | |
| 700 | 1 | |a Merkel, Peter A |e verfasserin |4 aut | |
| 700 | 1 | |a Ostergaard, Mikkel |e verfasserin |4 aut | |
| 700 | 1 | |a Saketkoo, Lesley Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Jasvinder A |e verfasserin |4 aut | |
| 700 | 1 | |a Strand, Vibeke |e verfasserin |4 aut | |
| 700 | 1 | |a Tugwell, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of rheumatology |d 1983 |g 41(2014), 5 vom: 12. Mai, Seite 994-9 |w (DE-627)NLM000019593 |x 1499-2752 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2014 |g number:5 |g day:12 |g month:05 |g pages:994-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3899/jrheum.131309 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2014 |e 5 |b 12 |c 05 |h 994-9 | ||